Global R&D Pipeline
My Favorite
Hot Targets:
STEAP1
Back
Total number of drugs
25
Phase II and later clinical stages
4%
Involving companies
21
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-STEAP1 CAR T-cells(PromiCell Therapeutics) | Anti-STEAP1 CAR T-cells(PromiCell Therapeutics) | CAR-T | Neoplasms Urogenital Diseases | STEAP1 inhibitors | Promicell, Inc. | Fred Hutchinson Cancer Research Center Promicell, Inc. | Phase 1/2 | - | - | - | - | - | - | - | - | - | Anti-STEAP1 CAR T-cells(PromiCell Therapeutics) | - | - | detail > | |
| CD8sp_CD28z STEAP1 CAR T | CD8sp_CD28z STEAP1 CAR T | CAR-T | Neoplasms Urogenital Diseases | CD28 agonists CD8 stimulants STEAP1 inhibitors | Oslo universitetssykehus HF | Oslo universitetssykehus HF | Preclinical | - | - | - | - | - | - | - | - | - | CD8sp_CD28z STEAP1 CAR T | - | - | detail > | |
| STEAP1 targeting CAR-T (Oslo University Hospital) | STEAP1 targeting CAR-T (Oslo University Hospital) | CAR-T | Neoplasms Urogenital Diseases | STEAP1 inhibitors | Oslo universitetssykehus HF | Oslo universitetssykehus HF | Preclinical | - | - | - | - | - | - | - | - | - | STEAP1 targeting CAR-T (Oslo University Hospital) | - | - | detail > | |
| STEAP1 Antibody Tubulysin Analog Conjugate(DAC Biotechnology) | STEAP1 Antibody Tubulysin Analog Conjugate(DAC Biotechnology) | Antibody drug conjugate (ADC) | Neoplasms Urogenital Diseases | STEAP1 inhibitors | Hangzhou DAC Biotechnology Co., Ltd. | Hangzhou DAC Biotechnology Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | STEAP1 Antibody Tubulysin Analog Conjugate(DAC Biotechnology) | - | - | detail > | |
| CD8sp_41BBz STEAP1 CAR T | CD8sp_41BBz STEAP1 CAR T | CAR-T | Neoplasms Urogenital Diseases | 4-1BB agonists CD8 stimulants STEAP1 inhibitors | Oslo universitetssykehus HF | Oslo universitetssykehus HF | Preclinical | - | - | - | - | - | - | - | - | - | CD8sp_41BBz STEAP1 CAR T | - | - | detail > | |
| NTX-470 | NTX-470 | mRNA encoding trispecific antibody Trispecific T-cell engager (TriTE) | Neoplasms Urogenital Diseases | CD3 stimulants PSMA inhibitors STEAP1 inhibitors | Nutcracker Therapeutics, Inc. | Nutcracker Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | NTX-470 | - | - | detail > | |
| CBD-IL-12 STEAP1 CAR-T | CBD-IL-12 STEAP1 CAR-T | CAR-T | Neoplasms Urogenital Diseases | STEAP1 inhibitors | Promicell, Inc. | Promicell, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | CBD-IL-12 STEAP1 CAR-T | - | - | detail > | |
| IgGsp_41BBz STEAP1 CAR T | IgGsp_41BBz STEAP1 CAR T | CAR-T | Neoplasms Urogenital Diseases | 4-1BB agonists STEAP1 inhibitors | Oslo universitetssykehus HF | Oslo universitetssykehus HF | Preclinical | - | - | - | - | - | - | - | - | - | IgGsp_41BBz STEAP1 CAR T | - | - | detail > | |
| Xaluritamig | Xaluritamig | Bispecific T-cell Engager (BiTE) | Neoplasms Urogenital Diseases | CD3 stimulants STEAP1 modulators | Amgen, Inc. | Amgen, Inc. BeiGene (Beijing) Co. Ltd. Xencor, Inc. | Phase 3 | Phase 1 | - | - | - | - | - | - | - | - | Xaluritamig | - | - | detail > | |
| ADRX-0405 | ADRX-0405 | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders Respiratory Diseases Urogenital Diseases | STEAP1 inhibitors TOP1 inhibitors | Adcentrx Therapeutics, Inc. | Adcentrx Therapeutics, Inc. | Phase 1 | - | - | - | - | Orphan Drug（United States） | - | Cleavable linker | - | 8 | ADRX-0405 | IgG1 - kappa | - | detail > |
Total 25 data
1
2
3
